| Recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T- NCT07137416 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones NCT06982222 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gyn NCT07226102 | City of Hope Medical Center | N/A |
| Recruiting | Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Met NCT06860815 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor R NCT05741164 | Emory University | Phase 2 |
| Recruiting | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Tri NCT07078604 | University of Washington | Phase 2 |
| Recruiting | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Loc NCT06434064 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic NCT06502691 | University of Washington | Phase 1 / Phase 2 |
| Recruiting | Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, NCT07158021 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Living Well With Advanced Breast Cancer NCT07227038 | Ohio State University Comprehensive Cancer Center | — |
| Recruiting | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative B NCT06324240 | Emory University | Phase 1 |
| Not Yet Recruiting | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer NCT04529044 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Horm NCT07112053 | University of Washington | Phase 2 |
| Recruiting | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Posit NCT06492759 | Emory University | Phase 2 |
| Recruiting | Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer NCT06525766 | Mayo Clinic | Phase 2 |
| Recruiting | An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Posit NCT06999798 | Mayo Clinic | Phase 1 |
| Withdrawn | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Tre NCT06590558 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Brea NCT06630325 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non- NCT06910761 | City of Hope Medical Center | Phase 2 |
| Recruiting | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis NCT06500481 | NRG Oncology | Phase 3 |
| Recruiting | Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast C NCT06518057 | University of Washington | Phase 2 |
| Withdrawn | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negat NCT05539365 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Terminated | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positiv NCT05554354 | National Cancer Institute (NCI) | Phase 2 |
| Completed | MBC Physical Activity Study NCT06500858 | Thomas Jefferson University | N/A |
| Recruiting | Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Rece NCT06260033 | City of Hope Medical Center | Phase 2 |
| Recruiting | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negat NCT06179303 | University of Washington | Phase 2 |
| Recruiting | Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Na NCT06026657 | Margaret Gatti-Mays | Phase 1 / Phase 2 |
| Withdrawn | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Tre NCT05807126 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastat NCT05756166 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Mobile Health for Adherence in Breast Cancer Patients NCT06112613 | ECOG-ACRIN Cancer Research Group | N/A |
| Terminated | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improvi NCT06315296 | Thomas Jefferson University | N/A |
| Suspended | Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With NCT05751668 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial NCT05967286 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy NCT06055881 | Mayo Clinic | N/A |
| Recruiting | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast NCT05318469 | Yuan Yuan | Phase 1 / Phase 2 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) NCT05673200 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tka Assay for CDK4/6i NCT06572800 | Yale University | N/A |
| Recruiting | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Ad NCT05372640 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer NCT05368506 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Recruiting | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard NCT05422794 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or L NCT05746325 | Mayo Clinic | N/A |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV NCT05417308 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Recruiting | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brai NCT05376878 | City of Hope Medical Center | Phase 4 |
| Recruiting | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple NCT04348747 | Roswell Park Cancer Institute | Phase 2 |
| Withdrawn | Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastati NCT05533320 | City of Hope Medical Center | N/A |
| Withdrawn | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Can NCT05093387 | Northwestern University | Phase 1 |
| Terminated | Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast NCT05198843 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy NCT05315687 | Emory University | Phase 2 |
| Withdrawn | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Ca NCT05244434 | City of Hope Medical Center | N/A |
| Recruiting | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer NCT05319873 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Can NCT05215769 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV T NCT05177796 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast Cancer NCT06206239 | Thomas Jefferson University | — |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer NCT05081492 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448 | University of Washington | Phase 1 |
| Completed | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel NCT04862585 | Ohio State University Comprehensive Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery NCT04588246 | NRG Oncology | Phase 3 |
| Terminated | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab NCT04639245 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer NCT04750473 | Emory University | Phase 1 |
| Active Not Recruiting | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases NCT04647916 | SWOG Cancer Research Network | Phase 2 |
| Terminated | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and P NCT04108858 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients NCT03606967 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520 | Pamela Munster | Phase 1 |
| Terminated | Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast NCT04190056 | University of California, San Francisco | Phase 2 |
| Withdrawn | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positiv NCT04756505 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer NCT04345913 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Recruiting | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Sol NCT04771520 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic NCT04418219 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | Nipple Aspirate Fluid in Detecting Breast Cancer NCT03715959 | Ohio State University Comprehensive Cancer Center | N/A |
| Suspended | Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring NCT04906369 | Mayo Clinic | — |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Withdrawn | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer NCT04351230 | Academic and Community Cancer Research United | Phase 2 |
| Withdrawn | Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal NCT04205071 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Recruiting | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer NCT04521764 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study NCT04316117 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Active Not Recruiting | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel NCT04090398 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer NCT04517838 | Mayo Clinic | — |
| Recruiting | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Ca NCT04090567 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study NCT04445844 | Mridula George, MD | Phase 2 |
| Recruiting | Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors NCT04526587 | Roswell Park Cancer Institute | — |
| Active Not Recruiting | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cance NCT03939897 | National Cancer Institute (NCI) | Phase 1 |
| Suspended | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer NCT04120246 | Veana Therapeutics | Phase 1 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Recruiting | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. NCT04305834 | City of Hope Medical Center | Phase 2 |
| Completed | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer NCT03554044 | University of California, San Francisco | Phase 1 |
| Withdrawn | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer NCT04249167 | Mayo Clinic | EARLY_Phase 1 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Suspended | Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer NCT03737695 | Mayo Clinic | — |
| Active Not Recruiting | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Ca NCT03941730 | Mayo Clinic | Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Completed | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Can NCT03207529 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Can NCT04256941 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases NCT03796273 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Completed | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating NCT03853707 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Recruiting | Intravital Microscopy in Human Solid Tumors NCT03823144 | Mayo Clinic | N/A |
| Withdrawn | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer NCT03803761 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis NCT03691493 | Emory University | Phase 2 |
| Completed | Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Communi NCT04297384 | Roswell Park Cancer Institute | N/A |
| Terminated | AMTEC IIT: Phase 2 Multiarm Study in TNBC NCT03801369 | Gordon Mills, MD, PhD | Phase 2 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative NCT03723928 | SWOG Cancer Research Network | N/A |
| Completed | Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Posi NCT03774472 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer NCT03579472 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer NCT03544125 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Brea NCT03524170 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast NCT03179904 | Mayo Clinic | Phase 2 |
| Completed | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer NCT03106077 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Canc NCT02849496 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT02453620 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival NCT02364557 | NRG Oncology | Phase 2 / Phase 3 |
| Active Not Recruiting | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Can NCT02115282 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer NCT01334021 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer NCT01149083 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive NCT00338728 | M.D. Anderson Cancer Center | Phase 2 |